Additional file 1: of Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study

ADRs leading to death. This table gives demographic and clinical characteristics of patients with an ADR whose outcome was death, and includes relevant details relating to their death. (DOCX 43 kb)